|
rs10017134
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A significant association with EOC was identified in the UGT2A1/2 region for the SNP rs10017134 (per allele OR = 1.4, 95% CI = 1.2-1.7, P = 1.2 × 10<sup>-6</sup> , BFDP = 0.02); and an association with HGSOC was identified in the EGFR region for the SNP rs114972508 (per allele OR = 2.3, 95% CI = 1.6-3.4, P = 1.6 × 10<sup>-5</sup> , BFDP = 0.29) and in the UGT2A1/2 region again for rs1017134 (per allele OR = 1.4, 95% CI = 1.2-1.7, P = 2.3 × 10<sup>-5</sup> , BFDP = 0.23).
|
31001917 |
2019 |
|
rs1002076
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that the rs17401966 variant AG/GG genotypes were significantly associated with a decreased risk of EOC (adjusted odds ratio (OR) = 0.81, 95 % confidence interval (CI) = 0.68-0.97), compared with the AA genotype, but no associations were observed for rs1002076.
|
25854172 |
2015 |
|
rs10069690
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A splicing variant in TERT, rs10069690, showed a statistically significant interaction with ET use for risk of serous ovarian cancer (p<sub>int</sub> = 0.013).
|
27420401 |
2016 |
|
rs10088218
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
|
rs10098821
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13.
|
22235027 |
2012 |
|
rs1017134
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A significant association with EOC was identified in the UGT2A1/2 region for the SNP rs10017134 (per allele OR = 1.4, 95% CI = 1.2-1.7, P = 1.2 × 10<sup>-6</sup> , BFDP = 0.02); and an association with HGSOC was identified in the EGFR region for the SNP rs114972508 (per allele OR = 2.3, 95% CI = 1.6-3.4, P = 1.6 × 10<sup>-5</sup> , BFDP = 0.29) and in the UGT2A1/2 region again for rs1017134 (per allele OR = 1.4, 95% CI = 1.2-1.7, P = 2.3 × 10<sup>-5</sup> , BFDP = 0.23).
|
31001917 |
2019 |
|
rs1024611
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These data suggest that MCP-1 rs1024611A/G and rs3760396C/G polymorphisms are associated with increased susceptibility to ovarian cancer, in which rs1024611A/G may increase serum level of MCP-1 in the Chinese population.
|
25289731 |
2015 |
|
rs10260419
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Overall EOC risk was associated with rs10260419 at chromosome 7p21.3 (OR = 1.33, P = 1.2 × 10<sup>-7</sup>) and rs74917072 at chromosome 2q37.3 (OR = 1.25, P = 4.7 × 10<sup>-7</sup>).
|
30898391 |
2019 |
|
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Cumulative risk analysis revealed 3 unfavorable variants that increased significantly the risk of developing ovarian cancer (p.Ile1145 = ABCB1+ p.Asp1853Asn ATM+ p.Ser406Ala ATP7B- OR 7,47; p = 0,002) and significantly modified the progression free survival (PFS) of the patients, and also two favorable genotypes which protected against ovarian cancer (p.Arg952Lys ATP7B+ p.Arg72Pro TP53- OR 0,50; p = 0,008).
|
25591549 |
2015 |
|
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In conclusion SNPs in WRAP53 (rs2287497 and rs2287498) have stronger association with an ovarian cancer risk than rs1042522 in TP53.
|
23192612 |
2013 |
|
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.
|
21952824 |
2012 |
|
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The rs1042522 polymorphism was not overall associated with o</span>varian cancer risk.
|
25060098 |
2014 |
|
rs1042838
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Five haplotypes occurred with greater than 5% frequency, and the haplotype carrying the V</span>660L variant had a significant association with ovarian cancer (odds ratio = 0.76, 95% confidence interval: 0.62, 0.92).
|
15718480 |
2005 |
|
rs1042838
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This meta-analysis suggests that the two polymorphisms of PGR, Alu insertion and Val660Leu, may contribute to ovarian cancer susceptibility as low-penetrance risk factors.
|
25228088 |
2015 |
|
rs1042838
|
|
|
0.030 |
GeneticVariation |
BEFREE |
No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer.
|
11323389 |
2001 |
|
rs1045485
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In the present study we investigate the relevance of RAD51 -135C > G, TP53 R72P, NQO1*2 and CASP8 D302H polymorphisms as potential modifiers of BC and/or OC susceptibility conferred by these mutations.
|
19214744 |
2010 |
|
rs1045485
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The minor allele of CASP8 D302H was significantly associated with a reduced risk of breast cancer (per-allele HR, 0.85; 95% CI, 0.76-0.97; P(trend) = 0.011) and ovarian cancer (per-allele HR, 0.69; 95% CI, 0.53-0.89; P(trend) = 0.004) for BRCA1 but not for BRCA2 mutation carriers.
|
20978178 |
2010 |
|
rs1045642
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our study represents the largest analysis of ABCB1 SNPs and EOC progression and survival to date, but has not identified additional signals, or validated reported associations with progression-free survival for rs1128503, rs2032582, and rs1045642.
|
23917080 |
2013 |
|
rs1046428
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We genotyped GSTA2_448_C > G (rs2180314), GSTA2_742_A > C (rs6577), GSTM2_-832_T > C (rs638820), GSTO1_-1242_G > A (rs2164624), GSTO1_419_A > C (rs4925), GSTO2_-183_A > G (rs2297235), GSTO2_342_A > G (rs156697), GSTZ1_-4378_A > G (rs1046428), and GSTZ1_94_G > A (rs3177427) by MALDI-TOF MS in the German GENICA breast cancer case-control collection of 1021 cases and 1015 controls and performed breast cancer risk association in general and with respect to the stratifications: menopausal status, family history of breast or ovarian cancer, use of oral contraceptives, use of hormone therapy, body mass index, and smoking as well as histopathological tumor characteristics including hormone receptor status, grade, histology, and node status.
|
19859803 |
2010 |
|
rs104886003
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We also found that an activating (E545K) Pik3ca mutation, unlike Pten inactivation or Pik3ca H1047R mutation, cannot cooperate with Arid1a loss to promote ovarian cancer development in the mouse.
|
26279473 |
2016 |
|
rs1048943
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Ile462Val status seems to represent a meaningful risk factor for ovarian cancer in Caucasians.
|
22733497 |
2012 |
|
rs1048943
|
|
|
0.020 |
GeneticVariation |
BEFREE |
CYP1A1 Ile462Val is a risk factor for ovarian cancer development.
|
22277800 |
2012 |
|
rs10505477
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Long non-coding RNA (lncRNA) CASC8 rs10505477 polymorphism has been identified to be related to risk of many kinds of cancers, such as colorectal cancer, gastric cancer, and invasive ovarian cancer, and it may be involved in the prognosis of gastric cancer patients who have received platinum-based chemotherapy after surgical treatment.
|
27249003 |
2016 |
|
rs1051740
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Overall results demonstrated that the association between <i>EPHX1</i> polymorphism rs1051740</span> and ovar</span>ian cancer risk had no statistical significance either in total analysis or in subgroup analyses by ethnicity and source of control.
|
31174441 |
2019 |
|
rs1051740
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The microsomal epoxide hydrolase Tyr113His polymorphism: association with risk of ovarian cancer.
|
11255266 |
2001 |